DekaBank Deutsche Girozentrale lifted its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) by 55.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 60,000 shares of the company's stock after acquiring an additional 21,500 shares during the period. DekaBank Deutsche Girozentrale's holdings in Recursion Pharmaceuticals were worth $651,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently made changes to their positions in RXRX. Swiss National Bank raised its position in shares of Recursion Pharmaceuticals by 7.6% in the 1st quarter. Swiss National Bank now owns 94,300 shares of the company's stock worth $675,000 after acquiring an additional 6,700 shares in the last quarter. Bank of New York Mellon Corp increased its position in Recursion Pharmaceuticals by 1.7% in the 1st quarter. Bank of New York Mellon Corp now owns 373,700 shares of the company's stock valued at $2,676,000 after buying an additional 6,294 shares in the last quarter. MetLife Investment Management LLC increased its position in Recursion Pharmaceuticals by 55.4% in the 1st quarter. MetLife Investment Management LLC now owns 64,035 shares of the company's stock valued at $458,000 after buying an additional 22,833 shares in the last quarter. Rhumbline Advisers increased its position in Recursion Pharmaceuticals by 4.0% in the 1st quarter. Rhumbline Advisers now owns 123,892 shares of the company's stock valued at $887,000 after buying an additional 4,818 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in Recursion Pharmaceuticals by 8.1% in the 1st quarter. Vanguard Group Inc. now owns 6,611,377 shares of the company's stock valued at $47,338,000 after buying an additional 497,504 shares in the last quarter. 63.62% of the stock is owned by institutional investors.

Insider Buying and Selling at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, major shareholder Mubadala Investment Co Pjsc bought 24,526 shares of the business's stock in a transaction dated Wednesday, January 25th. The shares were purchased at an average price of $7.88 per share, for a total transaction of $193,264.88. Following the purchase, the insider now directly owns 12,346,258 shares of the company's stock, valued at $97,288,513.04. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. In other news, Director Blake Borgeson sold 8,885 shares of the business's stock in a transaction that occurred on Tuesday, January 24th. The stock was sold at an average price of $8.71, for a total value of $77,388.35. Following the transaction, the director now owns 7,611,827 shares in the company, valued at approximately $66,299,013.17. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Mubadala Investment Co Pjsc acquired 24,526 shares of the company's stock in a transaction that occurred on Wednesday, January 25th. The stock was purchased at an average price of $7.88 per share, for a total transaction of $193,264.88. Following the purchase, the insider now owns 12,346,258 shares of the company's stock, valued at approximately $97,288,513.04. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 322,253 shares of company stock worth $2,427,260 and sold 208,598 shares worth $1,944,525. Company insiders own 22.25% of the company's stock.

Recursion Pharmaceuticals Trading Down 0.4 %

Recursion Pharmaceuticals (NASDAQ:RXRX – Get Rating) last released its quarterly earnings results on Tuesday, November 8th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.36) by $0.01. The business had revenue of $13.16 million during the quarter, compared to the consensus estimate of $6.43 million. Recursion Pharmaceuticals had a negative return on equity of 53.04% and a negative net margin of 860.34%. On average, equities research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.37 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently commented on the company. SVB Leerink decreased their target price on Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating for the company in a research report on Monday. The Goldman Sachs Group boosted their target price on Recursion Pharmaceuticals from $8.00 to $9.00 and gave the company a "neutral" rating in a research report on Wednesday, November 9th.

Recursion Pharmaceuticals Profile

(Get Rating)

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis.

Recommended Stories

• Get a free copy of the StockNews.com research report on Recursion Pharmaceuticals (RXRX)
• EVs, Robotics Among Growth Drivers As Chipmaker STMicro Gaps Up
• Does Oil Services Firm NOV Have Enough Energy To Maintain Rally?
• Shopify Clears Cup-With-Handle Base: Can Momentum Continue?
• The Future Of E-Commerce: Analysis And New Data
• Chevron Delights Shareholders with $75 Billion in Share Buybacks

Want to see what other hedge funds are holding RXRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating).

Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.